| NCT ID | NCT07118306 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Viz.ai, Inc. |
| Condition | COPD (Chronic Obstructive Pulmonary Disease) |
| Study Type | OBSERVATIONAL |
| Enrollment | 485 participants |
| Start Date | 2026-02-27 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 485 participants in total. It began in 2026-02-27 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.
Eligibility Criteria
Inclusion Criteria: * Patients aged 40 years or older at the time of arrival to the emergency department. * Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation. * A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. * A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for \>24 hours in emergency department/urgent care facility or resulting in death. * Patients on dual (LABA/LAMA, LABA/ICS, LAMA/ICS) or triple (LABA/LAMA/ICS) long-acting bronchodilator inhalers. Exclusion Criteria: * Patients on bronchodilator inhaler monotherapy. * Patients leaving against medical advice or expiring during hospitalization. * Patients with tracheostomy. * Patients with advanced cancer. * Patients who have received a lung transplant. * Discharge to hospice care. * Transfer to another hospital.
Frequently Asked Questions
Who can join the NCT07118306 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying COPD (Chronic Obstructive Pulmonary Disease). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07118306 currently recruiting?
Yes, NCT07118306 is actively recruiting participants. Visit ClinicalTrials.gov or contact Viz.ai, Inc. to inquire about joining.
Where is the NCT07118306 trial being conducted?
This trial is being conducted at Park Ridge, United States, Cherry Hill, United States, Philadelphia, United States, Falls Church, United States and 1 additional location.
Who is sponsoring the NCT07118306 clinical trial?
NCT07118306 is sponsored by Viz.ai, Inc.. The trial plans to enroll 485 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.